At low concentrations (0.25–1.0 μM in plasma) the drug blocks cell growth and promotes terminal differentiation by disrupting the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) oncogenic fusion protein, characteristic of APL. This evidence concerns the gene PML and acute promyelocytic leukemia.